<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868255</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0156</org_study_id>
    <nct_id>NCT02868255</nct_id>
  </id_info>
  <brief_title>Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma</brief_title>
  <acronym>MDScan</acronym>
  <official_title>Myeloid Derived Suppressor Cells Control by SIRP-alpha: Investigation in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      project is to study and develop anti-Signal Regulatory Protein α (SIRPα) antibodies (Ab) as a
      new immunotherapy strategy in cancer.

      Samples harvested from hepatocellular carcinoma (HCC) and ovarian cancer patients will be
      used in evaluation of the SIRP-CD47 expression and of the effect of the anti-human Signal
      Regulatory Protein (hSIRP) Ab on various cellular types from patients and healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of the SIRP/CD47 expression</measure>
    <time_frame>baseline</time_frame>
    <description>samples harvested from HCC and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-hSIRP Ab on various cellular types from patients</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ascites</arm_group_label>
    <description>30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank &quot;hépato-gastroentérologie du CHU de Nantes&quot; (declared under the reference DC-2011-1399).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resections</arm_group_label>
    <description>30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank &quot;hépato-gastroentérologie du CHU de Nantes&quot; (declared under the reference DC-2011-1399).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blood samples</arm_group_label>
    <description>blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection &quot;hépato-gastroentérologie du CHU de Nantes&quot; (declared under the reference DC-2011-1399).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of human samples</intervention_name>
    <description>Several types of samples will be used to test the effect of the drug candidate</description>
    <arm_group_label>Ascites</arm_group_label>
    <arm_group_label>Resections</arm_group_label>
    <arm_group_label>blood samples</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and ascites will be analyzed for various cell populations by flow cytometry (different
      myeloid subsets including polymorphonuclear cells, MDSC and monocytes, T cell sub-populations
      including Tregs, CD8 and CD4 T cells, , B cells, and immature and mature NK cell). Myeloid
      infiltrate will be also evaluated by immunochemistry staining of CD68, CD163, CD206 and SIRPα
      of HCCs from the tumour bank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Several types of samples will be used to test the effect of the drug candidate: 30
        inflammatory ascites of HCC patients, 30 HCC resections (both from CHU de Nantes), 30 HCC
        patient blood samples.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult

          -  HCC patients (all BCLC stages accepted)

          -  patient consent for the use of their biological samples

        Exclusion Criteria:

          -  patient with other cancers

          -  hepatitis C or B positive

          -  HCC treatment by chemo-embolization under 3 months

          -  under Sorafenib treatment within the month prior to collection

          -  underage or under guardianship patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle ARCHAMBEAUD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle ARCHAMBEAUD, Dr</last_name>
    <phone>02 40 08 31 52</phone>
    <email>isabelle.archambeaud@chu-nantes.fr</email>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biobank analyses</keyword>
  <keyword>Effect evaluation of the drug</keyword>
  <keyword>patient-derived cells</keyword>
  <keyword>SIRPα/CD47 expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

